LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akcijų sąrašas・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

16.65 2.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.14

Max

16.88

Pagrindiniai rodikliai
By Trading Economics
Pajamos	614M 331M
Pardavimai	288M 731M
P/E Sektoriaus vid.	48.586 49.888
Pelnas, tenkantis vienai akcijai	3.16
Pelno marža	45.287
Darbuotojai	835
EBITDA	628M 375M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+36.45% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-531M 1.8B
Ankstesnė atidarymo kaina	14.06
Ankstesnė uždarymo kaina	16.65

Naujienos nuotaikos

By Acuity

50%

155 / 344 reitingas Healthcare

Sarepta Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-29 15:04; UTC

Pagrindinės rinkos jėgos

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

2025-07-21 11:31; UTC

Pagrindinės rinkos jėgos

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-01-26 09:55; UTC

Karštos akcijos

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

2025-11-04 14:39; UTC

Uždarbis

Karštos akcijos

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

2025-11-04 12:45; UTC

Uždarbis

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

2025-08-11 11:48; UTC

Uždarbis

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025-08-11 11:11; UTC

Uždarbis

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025-07-29 21:11; UTC

Uždarbis

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

2025-07-29 12:14; UTC

Uždarbis

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

2025-07-29 11:46; UTC

Uždarbis

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

2025-07-21 12:53; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

2025-07-21 11:17; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

2025-07-21 10:25; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

2025-07-21 09:50; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025-07-21 09:12; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025-07-17 16:44; UTC

Uždarbis

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

2025-07-17 13:48; UTC

Uždarbis

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

2025-07-17 10:57; UTC

Uždarbis

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

2025-07-17 09:08; UTC

Karštos akcijos

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

2025-06-17 09:10; UTC

Karštos akcijos

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025-06-17 08:59; UTC

Karštos akcijos

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025-06-16 08:55; UTC

Karštos akcijos

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Akcijų palyginimas

Kainos pokytis

Sarepta Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

36.45% į viršų

12 mėnesių prognozė

Vidutinis 22.16 USD 36.45%

Aukščiausias 38 USD

Žemiausias 5 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sarepta Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

20 ratings

Pirkti

Laikyti

Parduoti

Remiantis 20 analitikų, pateikusių Sarepta Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

155 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.